In Q1 FY2026 (ended March 31, 2026), Enliven Therapeutics reported no revenue and a net loss of $23.6 million, a 17.2% improvement year-over-year. Operating loss was $27.8 million, improving 12.2% from the prior year. Diluted EPS was -$0.38, a 33.3% improvement. The company held $132.2 million in cash and $453.4 million in equity, with no long-term debt.
•Net loss of $23.6 million improved 17.2% year-over-year.
•Operating loss of $27.8 million improved 12.2% year-over-year.
•Diluted EPS of -$0.38 improved 33.3% year-over-year.
•Cash of $132.2 million and equity of $453.4 million with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia
ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and HER2 mutant tumors. Founded in 2019, the company is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule inhibitors to treat patients with cancer. Its pipeline includes two lead programs: ELVN-001, a small molecule kinase inhibitor in Phase 1 clinical trials for adults with chronic myeloid leukemia, and ELVN-002, a central nervous system penetrant and irreversible HER2 inhibitor in Phase 1 trials for non-small cell lung cancer and HER2 mutant tumors. The company aims to address unmet medical needs in oncology by targeting specific genetic drivers of cancer.
On which stock exchange is Enliven Therapeutics listed and what is its ticker symbol?
Enliven Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ELVN. The company's shares are traded in US dollars (USD). As a publicly traded biopharmaceutical firm, investors can buy and sell ELVN shares on this major US exchange.
What sector and industry does Enliven Therapeutics belong to?
Enliven Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing novel small molecule inhibitors for cancer treatment. Biotechnology companies like Enliven use biological processes and molecular biology to create therapies, often targeting specific genetic mutations or pathways involved in disease.
Where is Enliven Therapeutics headquartered and when was it founded?
Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado, United States. The company was founded in 2019, making it a relatively young player in the biotechnology space. Its location in Boulder places it within a vibrant life sciences hub, which may provide access to talent, research collaborations, and a supportive ecosystem for drug development.
What are the main drug candidates in Enliven Therapeutics' pipeline?
Enliven Therapeutics' pipeline currently features two clinical-stage programs. ELVN-001 is a small molecule kinase inhibitor in Phase 1 trials for chronic myeloid leukemia in adults. ELVN-002 is a CNS-penetrant and irreversible HER2 inhibitor in Phase 1 trials for non-small cell lung cancer and HER2 mutant tumors. Both candidates are designed to target specific molecular drivers of cancer, potentially offering more precise and effective treatment options for patients.